FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.96 USD
0 (0%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
248.12M
54.52M
91.5M
100.39M
37.86M
31.92M
26.91M
22.69M
19.13M
16.12M
Revenue %
-
-78.03
67.81
9.72
-62.28
-15.69
-15.69
-15.69
-15.69
Ebitda
-131.45M
-297.16M
-251.38M
-206.42M
-98.45M
-28.92M
-24.38M
-20.55M
-17.33M
-14.61M
Ebitda %
-52.98
-545.03
-274.74
-205.62
-260.01
-90.6
-90.6
-90.6
-90.6
Ebit
-144.64M
-313.56M
-262.91M
-216.7M
-105.54M
-29.26M
-24.67M
-20.79M
-17.53M
-14.78M
Ebit %
-58.29
-575.11
-287.34
-215.87
-278.75
-91.66
-91.66
-91.66
-91.66
Depreciation
13.19M
16.4M
11.53M
10.29M
7.1M
4.91M
4.14M
3.49M
2.94M
2.48M
Depreciation %
5.32
30.08
12.6
10.25
18.74
15.4
15.4
15.4
15.4
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
